Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
Haozhou Tan, Yanmei Hu, Prakash D. Jadhav, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7561-7580
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 402
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 79
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
Brian Sanders, Suman Pokhrel, Audrey Labbé, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 61
COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
İlker Polatoğlu, Tülay Öncü Öner, Irem Dalman, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 45
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Bin Tan, Xiaoming Zhang, Ahmadullah Ansari, et al.
Science (2024) Vol. 383, Iss. 6690, pp. 1434-1440
Open Access | Times Cited: 45
SARS‐CoV‐2 Papain‐Like Protease: Structure, Function and Inhibition
Sven Ullrich, Christoph Nitsche
ChemBioChem (2022) Vol. 23, Iss. 19
Open Access | Times Cited: 43
Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents
Lara Alzyoud, Mohammad A. Ghattas, Noor Atatreh
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 2463-2478
Open Access | Times Cited: 42
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 40
Targeting SARS-CoV-2 papain-like protease in the postvaccine era
Anh‐Tien Ton, Mohit Pandey, Jason R. Smith, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 11, pp. 906-919
Open Access | Times Cited: 38
Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro
Hossein Mousavi, Behzad Zeynizadeh, Mehdi Rimaz
Bioorganic Chemistry (2023) Vol. 135, pp. 106390-106390
Open Access | Times Cited: 26
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 25
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 10
The Chiral 5,6-Cyclohexane-fused Uracil Ring-System: a Molecular Platform with Promising Activity against SARS-CoV-2
Enrico Marcantonio, Debora Guazzetti, Crescenzo Coppa, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117302-117302
Closed Access | Times Cited: 1
Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
Prakash D. Jadhav, Xueying Liang, Ahmadullah Ansari, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors
Bin Tan, M. Sacco, Haozhou Tan, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115667-115667
Open Access | Times Cited: 20
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19
Fatema Hersi, Anusha Sebastian, Hamadeh Tarazi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115380-115380
Open Access | Times Cited: 17
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 16
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 6
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2
Wenying Yu, Yucheng Zhao, Hui Ye, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16252-16267
Closed Access | Times Cited: 25
Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
Jerneja Kladnik, Ana Dolinar, Jakob Kljun, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2158-2168
Open Access | Times Cited: 23
Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential
Mohammed Salah Ayoup, Mariam M. ElShafey, Hamida Abdel‐Hamid, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115272-115272
Open Access | Times Cited: 13
Structure-based design of SARS-CoV-2 papain-like protease inhibitors
Prakash D. Jadhav, Bo Huang, J. Osipiuk, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 116011-116011
Open Access | Times Cited: 13
Discovery of Pyrano[2,3-c]pyrazole Derivatives as Novel Potential Human Coronavirus Inhibitors: Design, Synthesis, In Silico, In Vitro, and ADME Studies
Abdou K. Allayeh, Aliaa H. El-boghdady, Mohamed A. Said, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 198-198
Open Access | Times Cited: 5
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Md. Easin Mia, Mithu Howlader, Farzana Akter, et al.
Clinical Pathology (2024) Vol. 17
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top